Question explored with the scientific record
Conversation so far
- 1 cholesterol
- 2 How do we decide target LDL levels for seniors or heart failure?
Answered on this page ↓
How do we decide target LDL levels for seniors or heart failure?
The short version: for seniors and heart failure patients, the evidence does not support aggressive LDL targets, and in heart failure, lower LDL is linked to higher death rates.
The 2025 post-hoc analysis of the HF-ACTION trial, which included 1,274 adults with chronic stable heart failure with reduced ejection fraction, found that patients with LDL below 100 mg/dL had a 57% higher risk of all-cause death than those with higher LDL, after adjusting for other risk factors [3]. Lower LDL did not reduce ischemic cardiovascular events at all [3]. This is the cholesterol paradox in heart failure: the sicker patients have lower cholesterol, and driving it lower does not appear to help.
For seniors without heart failure, a 2023 meta-analysis of 29 randomized trials covering 21,492 people aged 75 or older found that each 1 mmol/L reduction in LDL lowered major vascular events by about 26% [4]. That benefit was similar to what younger patients get. But the same meta-analysis found no significant difference between statin and non-statin drugs, and the benefit was driven largely by one open-label trial [4]. The absolute risk reduction was modest.
The 2017 FOURIER trial of evolocumab, a PCSK9 inhibitor, showed a 15% relative risk reduction in cardiovascular events over 2.2 years, but the absolute numbers were 9.8% versus 11.3% [1]. That is about 1.5 fewer events per 100 people treated. The trial was funded by the manufacturer, Amgen [1]. The 2024 review of evolocumab claims a 23% reduction in cardiovascular death during extended follow-up, but this is from a narrative review, not a new trial [2].
| Population | What the evidence shows |
|---|---|
| Heart failure patients | LDL below 100 mg/dL linked to 57% higher death risk; no fewer ischemic events [3] |
| Seniors 75+ | 26% relative risk reduction per 1 mmol/L LDL drop; modest absolute benefit [4] |
| High-risk patients on PCSK9 | 1.5 fewer events per 100 people over 2.2 years [1] |
The retrieved studies do not include any trial that set a specific LDL target for seniors or heart failure patients and compared it to a different target. The targets in guidelines are extrapolated from trials that enrolled mostly middle-aged people. The 2025 HF-ACTION analysis directly challenges the idea that lower is better in heart failure [3].
My call: for seniors without heart disease, modest LDL lowering may help, but the benefit is small and the evidence for aggressive targets is thin. For heart failure patients, the data says lower LDL is associated with higher mortality, not lower. Confidence: moderate.
Sources used 4
-
Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial)
The FOURIER trial demonstrated that evolocumab therapy significantly reduces residual cardiovascular risk in patients with atherosclerotic cardiovascular disease despite statin treatment, achieving a 15% relative risk reduction in major cardiovascular events over a median follow…
DOI: 10.1016/j.amjcard.2017.06.063 -
Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease
A narrative review concludes that evolocumab produces large LDL-C reductions, reduces cardiovascular risk, and appears safe across clinical trials and real-world studies, supporting intensive LDL-C lowering even at very low achieved levels.
DOI: 10.31083/j.rcm2505190 -
LDL cholesterol and clinical outcomes in heart failure with reduced ejection fraction a competing risk analysis
This post-hoc analysis of the HF-ACTION trial in 1,274 adults with chronic stable HFrEF shows that lower baseline LDL-C (<100 mg/dL) is associated with higher all-cause mortality but not with ischemic cardiovascular events, suggesting that aggressive LDL-C lowering may not reduc…
DOI: 10.1038/s41598-025-24832-9 -
Meta-Analysis of Lowering LDL Cholesterol and its Impact on the Cardiovascular System
In this meta-analysis of 29 RCTs, LDL cholesterol lowering reduced major vascular events by 26% per 1 mmol/L in older adults, with risk reduction comparable to younger patients and no significant statin/non-statin difference.
DOI: 10.53350/pjmhs20231758